New shot option for nerve disease? study tests weekly vs IV treatment

NCT ID NCT07540221

Recruiting now Disease control Sponsor: Grifols Therapeutics LLC Source: ClinicalTrials.gov ↗

First seen Apr 29, 2026 · Last updated Apr 29, 2026

Summary

This study compares two medicines for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a nerve disorder. It aims to see if XEMBIFY, given as a weekly shot under the skin, provides similar drug levels as Gamunex-C, given into a vein every 3 weeks. About 40 adults with stable CIDP will take part. The goal is to offer a more convenient treatment option.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIDP (CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

GC2402 Study Site 105
RECRUITING

Miami, Florida, 33067, United States

Contact Email: •••••@•••••
GC2402 Study Site 109
RECRUITING

Coral Springs, Florida, 33155, United States

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CIDP (CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY)